Thymic stromal lymphopoietin: Next research hotspot of carcinogenesis?

Tong Wu, Juan Wang, Lihua Jia, Bin Cheng

Department of Oral Medicine, Guanghua School of Stomatology, Sun Yat-sen University, Guangzhou, China.

DOI: 10.4236/abb.2012.326086                

Abstract

Thymic stromal lymphopoietin (TSLP) is an epithetlial cell derived cytokine which has been reported to be a master regulator in T helper (Th) 2 driven inflammation. Through acting on dentritic cells (DCs), granulocytes, natural killer T cells or directly on CD4+ T cells, TSLP plays significant roles in the pathogenesis of atopic diseases consisting of the triad of asthma, allergic rhinitis and atopic dermatitis. Recently mounting evidence demonstrated that cancer-related inflammation play decisive roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion, and metastasis. As a crucial regulator of Th2 driven inflammation, the involvement of TSLP in carcinogenesis have attracted researchers’ attention. However, the mechanisms of TSLP’s involvement in carcinogenesis are still largely unknown. In this review we first outline the roles of TSLP involved in allergic inflammation and then we further focus on the recent findings on TSLP’s tumor promoting activities hoping to provide hints on elucidation of the TSLP implication in carcinogenesis in future studies.

Keywords

Thymic Stromal Lymphopoietin; Inflammation; Cancer; Carcinogenesis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	He R, Geha RS. Thymic stromal lymphopoietin. Ann N Y Acad Sci. 2010;1183:13-24.
[2]	Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005;202(9):1213-23.
[3]	Lambrecht BN, Hammad H. Biology of lung dendritic cells at the origin of asthma. Immunity. 2009;31(3):412-24.
[4]	Zhang Y, Zhou B. Functions of thymic stromal lymphopoietin in immunity and disease. Immunol Res. 2012;52(3):211-23.
[5]	Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H, Ziegler SF. The multiple facets of thymic stromal lymphopoietin (TSLP) during allergic inflammation and beyond. J Leukoc Biol. 2012;91(6):877-86.
[6]	Takai T. TSLP expression: cellular sources, triggers, and regulatory mechanisms. Allergol Int. 2012;61(1):3-17.
[7]	Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073-81.
[8]	Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99.
[9]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
[10]	Li H, Zhao H, Yu J, Su Y, Cao S, An X, Ren X. Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin. Cancer Immunol Immunother. 2011;60(11):1587-96.
[11]	De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208(3):469-78.
[12]	Pedroza-Gonzalez A, Xu K, Wu TC, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med. 2011;208(3):479-90.
[13]	Friend SL, Hosier S, Nelson A, et al. A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells. Exp Hematol. 1994;22(3):321-8.
[14]	Quentmeier H, Drexler HG, Fleckenstein D, et al. Cloning of human thymic stromal lymphopoietin (TSLP) and signaling mechanisms leading to proliferation. Leukemia. 2001;15(8):1286-92.
[15]	Pandey A, Ozaki K, Baumann H, et al. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat Immunol. 2000;1(1):59-64.
[16]	Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol. 2010;11(4):289-93.
[17]	Watanabe N, Wang YH, Lee HK, et al. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature. 2005;436(7054):1181-5.
[18]	Wang YH, Liu YJ. OX40-OX40L interactions: a promising therapeutic target for allergic diseases? J Clin Invest. 2007;117(12):3655-7.
[19]	Liu YJ. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol. 2007;120(2):238-44.
[20]	Yoo J, Omori M, Gyarmati D,et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med. 2005;202(4):541-9.
[21]	Redhu NS, Gounni AS. Function and mechanisms of TSLP/TSLPR complex in asthma and COPD. Clin Exp Allergy. 2011 Dec 14. doi: 10.1111/j.1365-2222.2011.03919.x. [Epub ahead of print]
[22]	Zhou B, Comeau MR, De Smedt T, et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol. 2005;6(10):1047-53.
[23]	Al-Shami A, Spolski R, Kelly J, et al. A role for TSLP in the development of inflammation in an asthma model. J Exp Med. 2005;202(6):829-39.
[24]	Olkhanud PB, Rochman Y, Bodogai M, et al. Thymic stromal lymphopoietin is a key mediator of breast cancer progression. J Immunol. 2011;186(10):5656-62.
[25]	Ohara M, Yamaguchi Y, Matsuura K, et al. Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother. 2009;58(3):441-7..
[26]	Li L, Chao QG, Ping LZ, et al. The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC. Cancer Biother Radiopharm. 2009;24(3):357-67.
[27]	Tokuno K, Hazama S, Yoshino S, et al. Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res. 2009;29(5):1527-32.
[28]	Strauss L, Bergmann C, Szczepanski M, et al. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13(15 Pt 1):4345-54.
[29]	Wu T, Jia L, Du R, et al. Genome-wide analysis reveals the active roles of keratinocytes in oral mucosal adaptive immune response. Exp Biol Med (Maywood). 2011;236(7):832-43.
[30]	Bose A, Chakraborty T, Chakraborty K, et al. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun. 2008;8:10.
[31]	Agarwal A, Rani M, Saha GK, et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest. 2003; 32(1-2):17-30.